Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.

Conclusions- This is the first report of a combination therapy with ponatinib and rapamycin promoting regression of VM. Mechanistically, the drug combination enhanced AKT inhibition compared with single drug treatment and reduced PLCγ and ERK activity. PMID: 30626204 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30626204?dopt=Abstract

Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 10, 2019 Category: Cardiology Authors: Li X, Cai Y, Goines J, Pastura P, Brichta L, Lane A, Le Cras TD, Boscolo E Tags: Arterioscler Thromb Vasc Biol Source Type: research

More News: Arteriosclerosis | Biology | Bleeding | Pain | Thrombosis